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Background: The survival benefits of colon cancer surveillance programs are well delineated, but less is known
about the magnitude of false positive testing. The objective of this study was to estimate the false positive rate and
positive predictive value of testing as part of a surveillance program based on national guidelines, and to estimate
the degree of testing and resource use needed to identify a curable recurrence.
Methods: Analysis of clinically significant events leading to suspicion of cancer recurrence, false positive events,
true cancer recurrences, time to confirmation of diagnosis, and resource use (radiology, blood samples,
colonoscopies, consultations) among patients included in a randomised colon cancer surveillance trial.
Results: 110 patients surgically treated for colon cancer were followed according to national guidelines for 1884
surveillance months. 1105 tests (503 blood samples, 278 chest x-rays, 209 liver ultrasounds, 115 colonoscopies) and
1186 health care consultations were performed. Of the 48 events leading to suspicion of cancer recurrence, 34
(71%) represented false positives. Thirty-one (65%) were initiated by new symptoms, and 17 (35%) were initiated by
test results. Fourteen patients had true cancer recurrence; 7 resections of recurrent disease were performed, 4 of
which were successful R0 metastasis Resections. 276 tests and 296 healthcare consultations were needed per R0
resection; the cost per R0 surgery was £ 103207. There was a 29% probability (positive predictive value) of recurrent
cancer when a diagnostic work-up was initiated based on surveillance testing or patient complaints.
Conclusion: We observed a high false positive rate and low positive predictive value for significant clinical events
suggestive of possible colorectal cancer relapse in the setting of a post-treatment surveillance program based on
national guidelines. Providers and their patients should have an appreciation for the modest positive predictive
value inherent in colorectal cancer surveillance programs in order to make informed choices, which maximize
quality of life during survivorship. Better means of tailoring surveillance programs based on patient risk would likely
lead to more effective and cost-effective post-treatment follow-up.
Trial registration: ClinicalTrials.gov identifier NCT00572143. Date of trial registration: 11th of December 2007.
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Colon cancer is the third most common cancer in the
western world, and surgery is the only curative treatment.
Approximately one-third of those resected will experience
recurrent disease with an expected survival of less than
two years [1]. Most patients treated with curative intent* Correspondence: knut.magne.augestad@telemed.no
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unless otherwise stated.are included in some form of surveillance program involv-
ing periodic evaluations to detect asymptomatic recur-
rence. Reviews comparing various surveillance programs
have suggested that more intensive surveillance strategies
tend to increase five-year overall survival by 5-10% [2,3].
However, all preventive programs have associated costs
and risks [4-7]. The survival benefits of a surveillance pro-
gram for colon cancer survivors are well known, but much
less is known about the potential negative impacts for pa-
tients and their loved ones [3]. False positive test results
may negatively impact quality of life (QoL) by leadingral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has occurred. On the other hand, false negative tests
may result in diagnostic delay during which a poten-
tially curable recurrent cancer may become inoperable.
In order to more rationally weigh benefits and harms of
post-operative surveillance programs, patients and pro-
viders need information to help them better understand
the implications of positive and negative test results [6].
In addition, it is important to understand the resource
use associated with work-up of suspected recurrence
and the benefit which can be expected in terms of op-
portunities for curative treatment of recurrence.
Previously, we have reported the cost-effectiveness and
QoL results from a Norwegian randomized trial compar-
ing general practitioner (GP) versus surgeon-organised
colon cancer surveillance according to national guidelines
[8,9]. In this work, we focus on the outcomes of individ-
uals who underwent a diagnostic work-up in response to a
positive surveillance test result or development of interval
symptoms that raised concern for recurrence. These out-
comes include whether the initial positive test results or
symptoms represented a false positive or whether they
served as the first sign of a true recurrence, as well as sub-
sequent resource use for both true and false positives.
Among patients with true positive tests or symptoms, we
examine the extent to which curative resection of recur-
rent disease was possible.
Methods
Data from a randomised trial assessing a colon cancer sur-
veillance program based on Norwegian National Guidelines
(ClinicalTrials.gov identifier NCT00572143), was linked to
follow-up data from the electronic medical records (EMRs)
of four Norwegian hospitals [8,9]. Patients who underwent
a diagnostic work-up as a result of a positive surveillance
test or symptoms suggesting possible recurrence were
identified, and subsequent health care resource utilization
was quantified. Patients were enrolled in the surveillance
program between June 1, 2007 and December 15, 2011.
Outcomes
Primary outcomes included 1) Positive predictive value
and false positive rates for initial positive surveillance test
results or symptoms suggestive of possible recurrence,Table 1 Norwegian Gastrointestinal Cancer Group (NGICG) 20
Examination/test Surveillan
1 3 6 9 12 15 1
Chest x-ray X X
Liver ultrasonography X X
Colonoscopy X
CEA measurement X X X X X X
Clinical examination X X X X X X2) subsequent resource use for patients with both true and
false positives, and 3) whether curative resection of recur-
rent disease was possible. Secondary outcomes included
time from initial detection to confirmation of recurrence,
number needed to test per curative resection of recur-
rence, and cost per curative resection of recurrence.
Ethics
The Regional Committee for Medical Research Ethics
(P REK NORD 79/ 2006) and the Norwegian Data In-
spectorate approved the research protocol; all patients
provided informed written consent.
Inclusion and exclusion criteria
Inclusion criteria were age less than 75 years with recent
curative surgery for Dukes’ stage A, B or C colon cancer.
Patients receiving postsurgical adjuvant chemotherapy
(some Dukes’ B and all Dukes’ C) were eligible to partici-
pate. Exclusion criteria were age greater than 75 years,
membership in a healthcare trust not participating in the
trial, inability to provide informed consent, and Dukes’
stage D cancer. Patients were followed for up to 2 years
(Table 1).
Description of the surveillance program
The GP- and surgeon-followed arms underwent the same
surveillance regimens based on Norwegian Gastrointes-
tinal Cancer Group 2007 surveillance guidelines (Table 1).
The surveillance period included in analyses included nine
surveillance cycles (one month through 24 months post-
operatively) with regular clinical examinations, CEA meas-
urement, chest x-ray, contrast-enhanced liver ultrasound
and colonoscopy according to the intervals described in
Table 1.
Hospitals, primary and secondary care professionals
Three local hospitals and one university hospital trust
participated. Approximately 100 patients with colon can-
cer are surgically treated annually at these four hospitals.
Approximately 550 GPs work in the health care trust.
Serious clinical events
A serious clinical event (SCE) was defined as an episode
leading to suspicion of cancer recurrence. An SCE could07 Surveillance Program
ce cycle (postoperative months)
8 21 24 30 36 42 48 54 60
X X X X X
X X X X X
X
X X X X X X X X X
X X X X X X X X X
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sultation or in the intervals between surveillance visits),
the clinical findings at surveillance visits or the findings
of surveillance tests. The symptoms and clinical findings
initiating a diagnostic check-up could include the follow-
ing: lesion suspicious for colorectal cancer at colonos-
copy or rectal examination; increased carcinoembryonic
antigen (CEA) values revealed by repeated measurements;
blood in the stool detected by the Hemofec (fecal occult
blood) test; unexplained abdominal pain; unexplained
weight loss of 5 kg during the previous three months;
palpable lymphadenopathy; possible metastatic lesions
on chest x-ray, liver ultrasound or CT scan; or other
signs or symptoms suggestive of cancer recurrence. The
time to recurrent cancer diagnosis was defined as the
time from an SCE (dated in the GP referral or hospital
electronic medical record [EMR]) until the completion
of the ensuing diagnostic work-up.
Data collection
Data on radiology tests, colonoscopies, blood tests, surgi-
cal consultations, surgeries, pathology studies, admissions,
and hospital discharges were abstracted from the EMRs of
all included patients and were used to identify SCEs. In
the case of missing information, the surgeons, GPs, or pa-
tients were interviewed by telephone. False positive SCEs
were considered to have occurred when an SCE triggered
a subsequent diagnostic work-up that ruled out recur-
rence. We identified successful R0 resections of recurrent
local or metastatic disease by examining the surgical and
postoperative pathology reports.
Statistics
Proportions were compared using 2x2 contingency tables,
and Chi Squared or Fisher’s exact tests with an alpha level
of 0.05. Continuous values were compared using t-tests
with a two-sided alpha value of 0.05. The results were
expressed using the mean differences for continuous out-
comes with the corresponding standard deviations (SD),
95% confidence intervals (CI), and associated p-values. P-
values were reported to three decimal places, and p-values
less than 0.001 were reported as p < 0.001. The surveil-
lance program’s positive predictive value was defined as
the proportion of SCEs that were true positives (i.e., true
cancer recurrences).
The economic evaluation of cost per R0 resection was
performed from a societal perspective. Cost elements
were converted into British pounds (BP £) at a rate of
BP £ = 9.39 Norwegian krone (NOK) (www.norges-bank.
no). Unit costs assigned to health care resources have
been previously reported [8]. To address the uncertainty
aspect of the cost per R0 metastases resections, we per-
formed a many-inputs/one-output sensitivity analyses,
with results expressed in a Tornado chart. All analyseswere performed using IBM SPSS Statistics v 19.0 (IBM
Company SPSS 2010) and Microsoft Excel for Mac
2011.
Results
A total of 110 patients surgically treated for colon cancer
met the inclusion criteria and were enrolled in the ran-
domised trial. Fifty-five were followed by their GPs and
55 were followed in a surgical outpatient department.
Overall, 85 patients (75%; GP 41 vs. surgeon 44) were
followed for at least 12 months, and 58 patients (52%;
GP 29 vs. surgeon 29) were followed for 24 months. The
total surveillance time was 1884 person-months; median
follow up time was 17 months. Overall, 1105 tests (col-
onoscopy n = 115, liver ultrasound n = 209, chest x-ray
n = 278, carcinoembryonic antigen n = 503) were per-
formed and 1186 consultations occurred (Table 2).
Serious clinical events and false positive tests
A total of 48 SCEs were identified; 31 (65%) were initiated
by emerging symptoms and 17 (35%) were initiated by test
findings. Abdominal pain (n = 14, 29%) and blood in the
stool (n = 10, 20%) were the most common presenting
complaints. There were no significant differences between
surgeons or GPs in terms of SCE occurrence or the time
to diagnosis (Table 3). Overall, 34 patients (30% of all trial
patients) experienced a false positive event. The positive
predictive value (i.e., the probability of a surveillance-
initiated SCE being confirmed as true colon cancer re-
currence) was 29% (surgeons 36% vs. GPs 23%).
Clinical presentation of colon cancer recurrence
Of the 48 patients with SCEs, 14 (29%) had colon cancer
recurrence. Symptoms were the most common initial in-
dication of recurrence (n = 7), followed by radiologically
detected lesions (n = 4) and elevated CEA levels (n = 3)
(Table 4).
Harms and benefits of cancer surveillance
In this surveillance program, 14 recurrences were de-
tected, seven subsequent surgeries were performed, and
four R0 resections of metastases were achieved by sur-
veilling 110 patients over a total of 1884 months. This
means that 276 tests and 296 healthcare consultations
were needed per R0 resection; the cost per R0 resection
was £ 103207.
A 25% increase in successful R0 metastases surgeries
decreased the cost per surgery to £ 82566 (sensitivity
analyses Figure 1). Three patients had asymptomatic but
incurable recurrences. Mean time from SCE to confirm-
ation of recurrence was 39 days (standard deviation
35 days). The mean quality of life was equal to that of
the general UK population (Table 5) [10].
Table 2 Demographics of the patients enrolled in a National CRC Surveillance Program
Variable Surgeon-surveillance n = 55 (%) GP-surveillance n = 55 (%) Total n = 110 (%) p value
Mean age (SD) 66.7 (7.3) 64.0 (8.7) 65.4 (8.1) ns
Male 32 (58.2) 33 (60.0) 65 (59.1) ns
Female 23 (41.8) 22 (40.0) 45 (40.9) ns
Tumour location
Coecum 13 (23.6) 13 (23.6) 26 (23.6) ns
Ascendens 9 (16.3) 5 (9.1) 14 (12.7) ns
Transversum 4 (7.2) 5 (9.1) 9 (8.1) ns
Decendens 1 (1.8) 4 (1.8) 5 (4.5) ns
Sigmoid 28 (50.9) 28 (50.9) 56 (50.9) ns
Type of surgery
Laparoscopic 14 (25.5) 11 (20.0) 25 (22.7) ns
Open 41 (74.5) 44 (80.0) 85 (77.3) ns
Tumour stage
Dukes A 12 (21.8) 11 (20.0) 24 (21.8) ns
Dukes B 25 (45.5) 30 (54.5) 55 (50.0) ns
Dukes C 18 (32.7) 14 (25.5) 32 (29.0) ns
Total surveillance months 942 942 1884 ns
Median surveillance (months) 17 17 17 NA
Surveillance tests n 513 592 1105 ns
Carcinoembryonic antigen CEA (%) 203 (39) 300 (51) 503 <0.001
Chest X-ray (%) 150 (29) 128 (21) 278 0.003
Liver ultrasound (%) 110 (21) 99 (17) 209 0.03
Colonoscopy (%) 50 (9) 65 (11) 115 ns
Consultations n 508 678 1186 ns
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Summary of findings
A representative population of patients surgically treated
for colon cancer was enrolled in a colon cancer surveil-
lance program based on Norwegian national guidelines,
with an expected normal variance of demographic factors
and colon cancer severity. The patients were followed for
up to two years (i.e., the period during which most cancer
recurrences manifest). Thirty percent (34 of 110) of all the
surveillance patients experienced false positive tests, and
the probability of having a cancer recurrence when a diag-
nostic check-up was initiated was 29%. Overall, 276 tests
were needed to save one patient from recurrent colon can-
cer, and the total cost per successful surgery for recurrence
was £ 103207.
Comparison of existing literature
The potential negative side effects (physical and psycho-
logical) and costs of cancer surveillance strategies have
not been well delineated [4-7]. None of the studies in-
cluded in the previous reviews of colorectal cancer sur-
veillance have provided any specific details of the harms
(mortality or morbidity) resulting from investigating ortreating recurrences [2,3]. However, a potential harm from
any secondary prevention program is well recognised to
be over-diagnosis and false positive tests [7,11].
Some researchers have investigated the psychological
effects of colorectal cancer surveillance [8,12,13]. None of
these studies have found deterioration in the patient QoL
with surveillance. Nevertheless, in recent meta-analyses,
it was shown that anxiety, rather than depression, was a
major problem among long-term cancer survivors. It is
unknown, however, what impact a cancer surveillance
program itself has on anxiety levels [14].
The challenge of postoperative cancer surveillance is
that a vast majority of patients must undergo a large
number of tests without any benefit, or even with some
potential harm, to identify a few patients with curable
recurrence. The high rate of false positive tests (n = 34,
30% of all surveillance patients) in this trial was more
than we expected and likely negatively impacts the pa-
tient’s and family’s QoL. False positive and true positive
tests in colorectal cancer surveillance have been addressed
in previous reviews [15]. According to Kievit et al., 370
positive surveillance tests (26 true positives, 7%) and 11
surgeries were required to provide one patient with a
Table 3 Serious clinical events with suspicion of cancer recurrence
Serious clinical event characteristics Surgeon-surveillance GP-surveillance Total p value
Surveillance (months) 942 942 1884 ns
Interval SCE 12 13 25 ns
Routine SCE 11 12 23 ns
Total SCE 22 26 48 ns
Symptom initiated SCE
Abdominal pain (n) 3 11 14 0.05
Blood in stool (n) 6 4 10 ns
Anaemia (n) 0 1 1 ns
Weight loss (n) 1 1 2 ns
Lymphadenopathy (n) 2 0 2 ns
Other findings (n) 1 1 2 ns
Total 13 18 31 ns
True cancer recurrence 4 3 7 ns
Test initiated SCE
Elevated CEA 2 4 6 ns
Radiology 6 3 9 ns
Colonoscopy 1 1 2 ns
Total 9 8 17 ns
True cancer recurrence 4 3 7 ns
False positive tests and symptoms (%) 14 (25%) 20 (36%) 34 (31%) ns
Program positive predictive value 0.36 0.23 0.29 ns
Diagnostics for potential recurrent cancer
CEA (repeated) 2 4 7 ns
Chest x-ray 4 3 6 ns
CEUS 2 6 6 ns
Colonoscopy 3 12 15 0.05
CT thorax/abdomen/liver 13 8 21 ns
PET 0 2 2 ns
Consultations 14 23 37 ns
Diagnostic work-up days (SD) 45 (45) 35 (28) 39 (35) ns
PPV: positive predictive value, which is the proportion of positive test/clinical findings that are true positives (i.e., true cancer recurrences). ns: not significant.
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vey, 1186 tests were performed during the 1884 person-
month surveillance period, which equals 276 tests per
successful R0 metastasis surgery. This finding aligned
with the results from another Norwegian survey, which
reported 270 tests per successful R0 resection [16]. The
estimated cost of £ 103207 per successful R0 metastases
resection is higher than reported by other authors.
Kørner et al. reported an estimated cost per R0 resec-
tion of £ 15278 (US $ 25289),
Identification of asymptomatic but incurable recurrent
disease through surveillance testing raises ethical and
quality of life considerations [5,17]. In our study, three
patients (21%, Table 4) had asymptomatic but incurable
colon cancer recurrence. These figures are somewhathigher than those in a previous study reporting 9% asymp-
tomatic but incurable disease detected in a surveillance
program [16].
The imperfect nature of specific surveillance tests
themselves (i.e., test sensitivity and specificity) can con-
tribute to the potential harms of surveillance. National
surveillance programs are often based on serial CEA
measurements, and this biomarker has several pitfalls
and shortcomings. A recent study showed that the diag-
nostic accuracy of serial CEA measurements is low and
is impacted by the cut-off value used [18]. Similarly,
radiological tests have varying sensitivity and specificity,
the latter of which impacts the rate of false positive
tests. For example, the rate of false positive tests in CT
chest scans has been reported to be as high as 30-50%;
Table 4 Clinical presentation of colon cancer recurrence
Case
no













1 F Elevated CEA Routine CEUS Disseminated 27 No Inoperable
PET CT
2 M Abdominal pain Interval CEUS Liver 21 No Inoperable
3 M Elevated CEA Routine CEA Disseminated 71 No Inoperable
CT thorax
CT abdomen
4 M Metastatic lesion detected at CEUS Routine CEUS Liver 4 Yes 38
CT thorax
CT abdomen
5 F Abdominal pain, normal CEA, CT
and CEUS, disseminated cancer
detected at laparotomy
Interval CEUS Disseminated 270 Yes 270
CT thorax
CT abdomen






7 M Metastatic lesion detected
chest x-ray
Routine CT thorax Lung 45 Yes 62
CT abdomen






9 M Weight loss Routine CT Thorax Lung 45 No Inoperable
Night sweating CT abdomen
10 M Metastatic lesion detected at chest-
x ray
Routine CT Thorax Lung 4 Yes 42
CT abdomen
11 M Metastatic lesion detected on CEUS Routine MR liver Liver 3 Yes 43
CT thorax
CT abdomen
12 F Abdominal pain Interval CT abdomen Disseminated 16 No Inoperable
CT thorax
13 M Elevated CEA Routine CT thorax Liver 30 No Inoperable
CT abdomen Lung
CT liver
14 F Occult blood in faeces Interval CT thorax Liver 31 Yes 35
CT abdomen
CEUS
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cians for post-treatment surveillance purposes [19].
Studies of secondary prevention practices around other
cancer types have explored potential harmful effects of
these programs. In a systematic review addressing screen-
ing for lung cancer using thoracic CT scans, most of the
detected lung nodules (> 90%) were benign, and invasivenonsurgical procedures in patients with benign lesions
were common [20]. Forty-six percent of patients reported
psychological distress while awaiting the confirmation of a
potential cancer diagnosis [21]. Thus, the potential harms
of a preventive program must be carefully weighed against
any benefits [20-22]. In the case of colonoscopic colorectal
cancer surveillance, the potential harms of the procedure
Figure 1 A sensitivity analysis varying the major cost factors. The base case per R0 resection was set as origo (£103,000). Variance in the
number of successful R0 metastases resections has a major impact on overall cost (range £ 82,566 to £ 123, 847).
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foration) coupled with the low rate of intraluminal
cancer recurrence, have led some to debate whether
colonoscopy should be routinely included in surveillance




Analysed surveillance months 110 patients for
1884 months
Cost per successful R0 resection (£) 103207
Screening tests per R0 metastases resection
Carcinoembryonic antigen CEA (n) 125
Chest x-ray (n) 70
Liver ultrasound (n) 52
Colonoscopies (n) 30
Total screening tests (n) 276
Total health care consultations (n) 296
Benefits
Number of cancer recurrences detected (n) 14
Probability of R0 metastasis surgery (%)* 57% (4 of 7 metastasis
surgeries)
Side effects
False positive events (n) 34 (31%)
Probability of recurrent cancer when diagnostic
check up i.e. surveillance positive predictive
value
29%
aMean days to SCE diagnosis (SD) 39 (35)
Asymptomatic but incurable metastases
recurrences
3 of 14 recurrences
(21%)
Quality of life
aMean EQ-5D VAS score (CI) 75.9 (74.5-77.3)
aMean EQ-5D Index score (CI) 0.862 (0.84-0.87)
*R0 surgery is defined as positive histological resection margins. aReported in
a previous publication [8]. Equals that of the general UK population [10].Strengths and limitations
This study has some strength. It represents the first trial
to analyse the potential side effects of colon cancer sur-
veillance, an area of considerable uncertainty. Jeffery and
Hider outlined this uncertainty around side effects of
colorectal cancer surveillance in their 2007 Cochrane re-
view [3]. This study has limitations. The trial was de-
signed to assess whether general practice surveillance
affected patient-specific QoL and cost-effectiveness com-
pared to surgeon-led surveillance [9]. A trial assessing
survival would require a larger sample size and a longer
surveillance time. We acknowledge that this choice of a
follow-up period might have impacted the observed fre-
quency of SCE and thus of recurrence. Thirteen percent
(n = 14) of trial patients had colon cancer recurrence;
this low recurrence rate was most likely related, at least
partly, to the short follow-up duration (median 17 months).
Therefore, our calculation of the cost per successful R0 re-
currence surgery might represent an overestimate. To ad-
dress this uncertainty, we performed a sensitivity analysis
in which we estimated the cost per R0 resection if a 25%
increase in successful resections was observed (Figure 1).
However, in our opinion, the analysed time period gives a
realistic overview of the magnitude and rate of side effects
in a colon cancer surveillance program.
Conclusion
Information on a range of outcomes should be available
to fully assess the net benefit or harm of colon cancer
surveillance. Any survival benefit of the surveillance must
be balanced against the potential harms inherent to ensure
that surveillance programs are acceptable. Providers are
best positioned to inform patients and their families of
these benefits and potential harms. The nature of postop-
erative cancer surveillance is that a vast majority of pa-
tients (96% in the present study) must undergo a large
number of tests without any benefit, or even with some
harm to themselves and their family, to identify a few pa-
tients with curable recurrence. Patients with asymptom-
atic but incurable disease (21% of all recurrences in the
present study) likely represent the most controversial
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[16]. The reported cost of £ 103207 per R0 resection of re-
current disease is significantly higher than that reported
by others [16].
In conclusion, due to the high rate of false positive
tests and low positive predictive value of the surveillance
program examined, we feel that a more tailored surveil-
lance approach based on recurrence risk and likely re-
currence pattern is needed in future CRC surveillance
programs. Such an approach has the potential to reduce
costs and the number of false positive tests, while im-
proving positive predictive value. There is nothing in the
current evidence base suggesting that such an approach
will compromise the potential survival benefit of CRC
surveillance. In addition, further research is needed re-
garding the potential harms of colorectal cancer surveil-
lance, including quality of life impacts due to false
positive surveillance tests and to early diagnosis of in-
curable recurrence. The estimated cost of surveillance
is considerable, and whether the identified costs are ac-
ceptable when comparing the benefits and harms is a
matter of discussion not only among policy and deci-
sion makers, but also among providers, patients, and
families.
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